Tailored Treatment Strategies in First Line Therapy for Ovarian Cancer Patients: A Critical Review of the Literature

Background: Ovarian cancer (OC) is a significant cause of cancer-related mortality in women globally, with a five-year survival rate of approximately 49%. Standard therapy involves cytoreductive surgery followed by chemotherapy. Its poor prognosis has driven interest in alternative therapies such as...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής

Κύριοι συγγραφείς:	Daniela Luvero, Roberto Angioli, Federica Celoro, Francesco Plotti, Corrado Terranova, Federica Guzzo, Gianna Barbara Cundari, Federico Liparulo, Camilla Verdone, Roberto Montera
Μορφή:	Artigo
Γλώσσα:	Inglês
Έκδοση:	MDPI AG 2024-06-01
Σειρά:	Pharmaceuticals
Θέματα:	ovarian cancer PARP inhibitors maintenance therapy bevacizumab
Διαθέσιμο Online:	https://www.mdpi.com/1424-8247/17/6/778
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!